Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats.

Hambuchen MD, Berquist MD, Simecka CM, McGill MR, Gunnell MG, Hendrickson HP, Owens SM.

J Pharm Pharm Sci. 2019;22(1):301-312. doi: 10.18433/jpps30471.

2.

Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats.

McClenahan SJ, Hambuchen MD, Simecka CM, Gunnell MG, Berquist MD, Owens SM.

Drug Alcohol Depend. 2019 Feb 1;195:140-147. doi: 10.1016/j.drugalcdep.2018.12.006. Epub 2019 Jan 4.

PMID:
30634109
3.

Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.

Hay CE, Gonzalez GA 3rd, Ewing LE, Reichard EE, Hambuchen MD, Nanaware-Kharade N, Alam S, Bolden CT, Owens SM, Margaritis P, Peterson EC.

PLoS One. 2018 Jun 29;13(6):e0200060. doi: 10.1371/journal.pone.0200060. eCollection 2018.

4.

The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats.

Hambuchen MD, Hendrickson HP, Gunnell MG, McClenahan SJ, Ewing LE, Gibson DM, Berquist MD, Owens SM.

Drug Alcohol Depend. 2017 Oct 1;179:347-354. doi: 10.1016/j.drugalcdep.2017.07.011. Epub 2017 Aug 8.

5.

Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum.

Hambuchen MD, Hendrickson HP, Owens SM.

Anal Methods. 2017 Jan 28;9(4):609-617. doi: 10.1039/C6AY03176E. Epub 2016 Dec 22.

6.

Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.

Hambuchen MD, Rüedi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM.

Hum Vaccin Immunother. 2016 Sep;12(9):2240-8. doi: 10.1080/21645515.2016.1179407. Epub 2016 May 10.

7.

Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.

Hambuchen MD, Carroll FI, Rüedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM.

J Med Chem. 2015 Jun 11;58(11):4665-77. doi: 10.1021/acs.jmedchem.5b00220. Epub 2015 May 22.

8.

The pharmacokinetics of methamphetamine self-administration in male and female rats.

Milesi-Hallé A, Hambuchen MD, McMillan DE, Michael Owens S.

Drug Alcohol Depend. 2015 May 1;150:164-9. doi: 10.1016/j.drugalcdep.2015.02.032. Epub 2015 Mar 9.

9.

Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.

Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB.

Hum Vaccin Immunother. 2014;10(9):2638-47. doi: 10.4161/hv.29707. Epub 2014 Nov 1.

10.

Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages.

Peterson EC, Hambuchen MD, Tawney RL, Gunnell MG, Cowell JL, Lay JO Jr, Blough BE, Carroll FI, Owens SM.

Bioconjug Chem. 2014 Dec 17;25(12):2112-5. doi: 10.1021/bc500456z. Epub 2014 Dec 4.

11.

Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.

Hambuchen MD, Rüedi-Bettschen D, Williams DK, Hendrickson H, Owens SM.

Vaccine. 2014 Oct 29;32(47):6213-9. doi: 10.1016/j.vaccine.2014.09.025. Epub 2014 Sep 22.

12.

Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.

Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):892-8. Review.

Supplemental Content

Loading ...
Support Center